WuXi STA and Dizal Pharmaceutical sign CMC development and manufacturing agreement

24 May 2019

WuXi STA will provide integrated CMC services from pre-clinical to commercial, for both API and formulation for Dizal Pharmaceutical research projects.

STA Pharmaceutical – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical have announced a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (chemical, manufacturing and control) process research and manufacturing services from API to drug product.

WuXi STA and Dizal Pharmaceutical sign CMC development and manufacturing agreement

Dizal Pharmaceutical is a research-based biotechnology joint venture company between AstraZeneca and Advanced Manufacturing Industry Investment Fund (FIIF) managed by private equity firm China Sate Development & Investment Corporation, dedicated to the discovery, development and commercialization of first-in-class/best-in-class medicines. Since its inception in October 2017, Dizal has worked closely with WuXi STA on CMC for an innovative drug.

Throughout this period, WuXi STA has provided process optimization, API manufacturing from grams to kilograms, drug product development and manufacturing for clinical trials, and IND filling in both China and the US. WuXi STA has utilized its innovative drug development and manufacturing platform, regulatory CMC support and quality systems to enable Dizal Pharmaceutical to successfully implement Phase I clinical research in China and the US.

The signing of the strategic cooperation agreement will further strengthen the deep and wide cooperation between the two companies. Dizal Pharmaceutical is currently leading several projects in the clinical development stage, covering physical and liquid tumors, chronic kidney disease, respiratory infections and other fields. In the future, WuXi STA will provide integrated CMC services from pre-clinical to commercial, for both API and formulation for Dizal Pharmaceutical research projects.

“We are delighted to sign a comprehensive strategic cooperation agreement with WuXi STA. The innovative capabilities and scale advantage of WuXi STA, as well as many excellent and experienced scientists, will empower us to potentially accelerate our project pipelines. Ultimately, bringing new therapies to China and the US more quickly.” said Dr Zhang Xiaolin, founder and CEO of Dizal Pharmaceutical.

Dr Minzhang Chen, CEO of WuXi STA, commented: “Our mission is to empower customers to develop innovative drugs from clinical to commercial – faster and more efficiently. We are delighted to become the strategic partner of Dizal Pharmaceutical and look forward to helping them advance their drug candidates towards the clinic, bringing innovative medicines for the benefit of patients around the world.”

Read More

Related news

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Catalent to open new clinical supply facility in San Diego

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more 
Velesco Pharma to triple its clinical manufacturing capacity

Velesco Pharma to triple its clinical manufacturing capacity

4 Sep 2019

Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.

Read more 
Taiwan's biggest CDMO secures FDA approval

Taiwan's biggest CDMO secures FDA approval

3 Sep 2019

Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Dutch company receives €20 million for skin cancer diagnostic test

Dutch company receives €20 million for skin cancer diagnostic test

3 Sep 2019

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

Read more